CLGN Stock Analysis: Buy, Sell, or Hold?
CLGN - CollPlant Biotechnologies Ltd Ordinary Shares
$3.67
0.05 (1.38%)
▲
5d:
+1.24%
30d:
-10.92%
90d:
+1050.83%
HOLD
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 25, 2026
Get Alerted When CLGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CLGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CLGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CLGN is currently trading at $3.67, which is considered fair relative to its 30-day fair value range of $3.50 to $4.10. From a valuation perspective, the stock is trading at a discount (Forward PE: -20.4) compared to its historical average (3.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CLGN is in a strong uptrend. Immediate support is located at $3.41, while resistance sits at $4.45.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.12 (+203.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CLGN is in a strong uptrend. Immediate support is located at $3.41, while resistance sits at $4.45.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.12 (+203.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.50 -
$4.10
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (46/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 203.0% below Wall St target ($11.12)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- NEUTRAL: Bottoming setup forming (46/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$3.50 -
$4.10
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.41
Resistance Level
$4.45
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.39
Wall Street Target
$11.12
(+203.0%)
Revenue Growth (YoY)
-39.7%
PE vs Historical
-20.4 vs 3.5
CHEAP
Share & Embed Analysis
Last updated: October 24, 2026 5:15 AM ET
Data refreshes hourly during market hours. Next update: 6:15 AM
Data refreshes hourly during market hours. Next update: 6:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 72 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 56 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 47 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$153 | 59 HOLD |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
15 analysts |
$108 | 61 BUY |
